Immunometabolic reprogramming via GLP-1 receptor agonists in people with HIV: A multidimensional systemic framework

More on GLP-1 receptor agonists

• Diabetes drug class linked to slightly less frailty progression

  Diabetes, Obesity & Metabolism · 8 Oct 2026

• SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs

  Diabetes & Vascular Disease Research · 4 Oct 2026

• GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk

  Diabetes, Obesity & Metabolism · 4 Oct 2026

• GLP-1 agonists linked to lower dementia risk after COVID-19

  Drug Design, Development and Therapy · 5 Oct 2026